Literature DB >> 28507805

Generation and functional characterization of MDSC-like cells.

Annkristin Heine1, Stefanie Andrea Erika Held1, Jonas Schulte-Schrepping2, Julia Friederike Andrea Wolff1, Kathrin Klee2, Thomas Ulas2, Niklas Arndt Schmacke2, Solveig Nora Daecke1, Kati Riethausen1, Joachim L Schultze2,3, Peter Brossart1.   

Abstract

Myeloid-derived suppressor cells (MDSC) are critical in regulating immune responses by suppressing antigen presenting cells (APC) and T cells. We previously observed that incubation of peripheral blood monocytes with interleukin (IL)-10 during their differentiation to monocyte-derived dendritic cells (moDCs) results in the generation of an APC population with a CD14+HLA-DRlowphenotype (IL-10-APC) with reduced stimulatory capacity similar to human MDSC. Co-incubation experiments now revealed that the addition of IL-10-APC to moDC caused a reduction of DC-induced T-cell proliferation, of the expression of maturation markers, and of secreted cytokines and chemokines such as TNF-α, IL-6, MIP-1α and Rantes. Addition of IL-10-APC increased the immunosuppressive molecule osteoactivin and its corresponding receptor syndecan-4 on moDC. Moreover, CD14+HLA-DRlow MDSC isolated from healthy donors expressed high levels of osteoactivin, which was even further upregulated by the auxiliary addition of IL-10. Using transcriptome analysis, we identified a set of molecules and pathways mediating these effects. In addition, we found that IL-10-APC as well as human isolated MDSC expressed higher levels of programmed death (PD)-1, PD-ligand-1 (PD-L1), glucocorticoid-induced-tumor-necrosis-factor-receptor-related-protein (GITR) and GITR-ligand. Inhibition of osteoactivin, syndecan-4, PD-1 or PD-L1 on MDSC by using blocking antibodies restored the stimulatory capacity of DC in co-incubation experiments. Activation of MDSC with Dectin-1 ligand curdlan reduced the expression of osteoactivin and PD-L1. Our results demonstrate that osteoactivin/syndecan-4 and PD-/PD-L1 are key molecules that are profoundly involved in the inhibitory effects of MDSC on DC function and might be promising tools for clinical application.

Entities:  

Keywords:  APC; GITR; IL-10; MDSC; PD-1; PD-L1; immunosuppression; osteoactivin; syndecan-4

Year:  2017        PMID: 28507805      PMCID: PMC5414884          DOI: 10.1080/2162402X.2017.1295203

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  40 in total

1.  Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses.

Authors:  Bhumika Sharma; Sonali Joshi; Antonella Sassano; Beata Majchrzak; Surinder Kaur; Priya Aggarwal; Behnam Nabet; Marinka Bulic; Brady L Stein; Brandon McMahon; Darren P Baker; Rikiro Fukunaga; Jessica K Altman; Jonathan D Licht; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2012-10-16       Impact factor: 5.157

2.  Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts.

Authors:  F F Safadi; J Xu; S L Smock; M C Rico; T A Owen; S N Popoff
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

3.  Glucocorticoid-induced leucine zipper: a critical factor in macrophage endotoxin tolerance.

Authors:  Jessica Hoppstädter; Sonja M Kessler; Stefano Bruscoli; Hanno Huwer; Carlo Riccardi; Alexandra K Kiemer
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

4.  Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity.

Authors:  Jin-Sung Chung; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2011-05-09       Impact factor: 5.532

5.  The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.

Authors:  Mark-Alexander Schwarzbich; Michael Gutknecht; Julia Salih; Helmut R Salih; Peter Brossart; Susanne M Rittig; Frank Grünebach
Journal:  Cancer Immunol Immunother       Date:  2011-08-27       Impact factor: 6.968

Review 6.  The effects of β-glucans on dendritic cells and implications for cancer therapy.

Authors:  Sabrin H Albeituni; Jun Yan
Journal:  Anticancer Agents Med Chem       Date:  2013-06       Impact factor: 2.505

Review 7.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

8.  The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.

Authors:  Jin-Sung Chung; Kyoichi Tamura; Hideo Akiyoshi; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2014-02-10       Impact factor: 5.422

9.  Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.

Authors:  Jin-Sung Chung; Irene Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

10.  The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.

Authors:  Jin-Sung Chung; Mizuki Tomihari; Kyoichi Tamura; Tetsuhito Kojima; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

View more
  22 in total

Review 1.  Recent advances in myeloid-derived suppressor cell biology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Front Med       Date:  2020-09-02       Impact factor: 4.592

Review 2.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 3.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

4.  Cysteine cathepsins L and X differentially modulate interactions between myeloid-derived suppressor cells and tumor cells.

Authors:  Tanja Jakoš; Anja Pišlar; Urša Pečar Fonović; Urban Švajger; Janko Kos
Journal:  Cancer Immunol Immunother       Date:  2020-05-05       Impact factor: 6.968

Review 5.  Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy.

Authors:  Hiroyuki Horiguchi; Tyler J Loftus; Russell B Hawkins; Steven L Raymond; Julie A Stortz; McKenzie K Hollen; Brett P Weiss; Elizabeth S Miller; Azra Bihorac; Shawn D Larson; Alicia M Mohr; Scott C Brakenridge; Hironori Tsujimoto; Hideki Ueno; Frederick A Moore; Lyle L Moldawer; Philip A Efron
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

6.  Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment.

Authors:  Xia Shao; Boting Wu; Luya Cheng; Feng Li; Yanxia Zhan; Chanjuan Liu; Lili Ji; Zhihui Min; Yang Ke; Lihua Sun; Hao Chen; Yunfeng Cheng
Journal:  J Transl Med       Date:  2018-03-02       Impact factor: 5.531

7.  Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets.

Authors:  Sergej Tomić; Bojan Joksimović; Marina Bekić; Miloš Vasiljević; Marijana Milanović; Miodrag Čolić; Dragana Vučević
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

Review 8.  Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity.

Authors:  Graham Pawelec; Chris P Verschoor; Suzanne Ostrand-Rosenberg
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

Review 9.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 10.  Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.

Authors:  Yuhui Yang; Chunyan Li; Tao Liu; Xiaofang Dai; Alexandr V Bazhin
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.